AgomAb Therapeutics N.V. American Shares
AGMB | NASDAQ
$7.49
-$0.46 (-5.79%)
At close: Oct 30, 2026, 4:00 PM ET
$7.49
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
TTM Period Ending | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a |
Operating Income | -31.88M | -27.17M | -11.81M |
Interest Income | 754K | 644K | 471K |
Pretax Income | -35.68M | -30.01M | -11.73M |
Net Income | -35.68M | -30.01M | -11.73M |
Selling & General & Admin | 5.89M | 4.02M | 1.38M |
Research & Development | 26.86M | 23.72M | 10.73M |
Other Expenses | -863K | -572K | -298K |
Operating Expenses | 31.88M | 27.17M | 11.81M |
Interest Expense | 124K | 124K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 31.88M | 27.17M | 11.81M |
Income Tax Expense | n/a | 4K | 4K |
Shares Outstanding (Basic) | 48.74M | 42.49M | 36.24M |
Shares Outstanding (Diluted) | 48.74M | 42.49M | 36.24M |
EPS (Basic) | -0.79 | -0.75 | -0.32 |
EPS (Diluted) | -0.79 | -0.75 | -0.32 |
EBITDA | -35.67M | -29.85M | -11.8M |
EBIT | -35.69M | -30.04M | -11.88M |
Depreciation & Amortization | 24K | 192K | 85K |
Add to Watchlist
Select watchlists to add or remove AGMB